https://www.socictopen.socict.org/files/original/73667da660c3a565e84b77f3853cb623.pdf fca2aa68188d31f0b79a8fa8d813041e Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource COVID-19 Drug Discovery Using Intensive Approaches Creator An entity primarily responsible for making the resource Ayumu Asai, Masamitsu Konno, Miyuki Ozaki, Chihiro Otsuka, Andrea Vecchione, Takahiro Arai, Toru Kitagawa, Ken Ofusa, Masami Yabumoto, Takaaki Hirotsu, Masateru Taniguchi, Hidetoshi Eguchi, Yuichiro Doki, Hideshi Ishii Description An account of the resource Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource COVID-19, coronavirus, infection, drug discovery, Drug repositioning Identifier An unambiguous reference to the resource within a given context DOI: 10.3390/ijms21082839 Source A related resource from which the described resource is derived International Journal of Molecular Sciences Publisher An entity responsible for making the resource available MDPI AG Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Biology (General), Chemistry Language A language of the resource EN